The DOI matches its Crossref record; 157 of the 159 references it cites were found in a registry or an index.
TIM3 comes of age as an inhibitory receptor
Open accessAbstract
T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and CD8+ T cells. Initial data indicated that TIM3 functioned as a 'co-inhibitory' or 'checkpoint' receptor, but due to the lack of a definable inhibitory signalling motif, it was also suggested that TIM3 might act as a co-stimulatory receptor. Recent studies have shown that TIM3 is part of a module that contains multiple co-inhibitory receptors (checkpoint receptors), which are co-expressed and co-regulated on dysfunctional or 'exhausted' T cells in chronic viral infections and cancer. Furthermore, co-blockade of TIM3 and programmed cell death 1 (PD1) can result in tumour regression in preclinical models and can improve anticancer T cell responses in patients with advanced cancers. Here, we highlight the developments in understanding TIM3 biology, including novel ligand identification and the discovery of loss-of-function mutations associated with human disease. In addition, we summarize emerging data from human clinical trials showing that TIM3 indeed acts as a 'checkpoint' receptor and that inhibition of TIM3 enhances the antitumour effect of PD1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, tyrosine kinase FYN and human leukocyte antigen B (HLA‐B)‐associated transcript 3 (BAT3) were suggested to inhibit the cytoplasmic tail of TIM‐3 signaling [307, 308, 309].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [307]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the latter of which encodes the checkpoint molecule TIM3, one of the most promising new therapeutic approaches in cancer 32 that was recently described in a GWAS as an AD risk gene 2 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Self-citationMiller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Self-citationDefining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Self-citationDefining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Weiss, G. J. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors. J. Immunother. Cancer 5, 86 (2017).
- Davar, D. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. J. Immunother. Cancer 6, 115 (2018).
Cited by
Sorted by citations
Items 401–500 of 963
Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future
Wei, H., Dong, C., & Li, X. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00462 · Cited by 16
The role of TIM-3 in sepsis: a promising target for immunotherapy?
Wang, C., Liu, J., Wu, Q., Wang, Z., Hu, B., & Bo, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328667 · Cited by 14
Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function
Veliz, K., Shen, F., Shestova, O. E., Shestov, M., Shestov, A. A., Sleiman, S., Hansen, T., O’Connor, R. S., & Gill, S. I. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200819 · Cited by 14
Zeidan, A. M., Bewersdorf, J. P., Hasle, V., Shallis, R. M., Thompson, E. G., Menezes, D. L. D., Rose, S., Boss, I. W., Halene, S., Haferlach, T., et al. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207241257904 · Cited by 16
Impaired mitochondrial oxidative phosphorylation induces CD8+ T cell exhaustion
Liu, M., Fu, X., Yi, Q., Xu, E., & Dong, L. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150738 · Cited by 14
Mewes, C., Alexander, T., Büttner, B., Hinz, J. M., Alpert, A., Popov, A., Ghadimi, M. B., Beißbarth, T., Tzvetkov, M. V., Grade, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218318 · Cited by 14
Halma, J., Pierce, S. H., McLennan, R., Bradley, T., & Fischer, R. T. (2021) · Clinical and Translational Science · doi:10.1111/cts.13208 · Cited by 13
Yoshikawa, K., Ishida, M., Yanai, H., Tsuta, K., Sekimoto, M., & Sugie, T. (2022) · Oncology Letters · doi:10.3892/ol.2022.13318 · Cited by 14
Mohty, R., Hamed, R. A., Bazarbachi, A. A., Brissot, É., Nagler, A., Zeidan, A. M., & Mohty, M. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01346-9 · Cited by 14
JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells
Eschweiler, S., Wang, A., Ramírez-Suástegui, C., Witzleben, A. V., Li, Y., Chee, S., Simon, H. A., Mondal, M., Ellis, M. J., Thomas, G. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112040 · Cited by 13
Matsumoto, H., Fujita, Y., Asano, T., Matsuoka, N., Temmoku, J., Sato, S., Yashiro‐Furuya, M., Watanabe, H., & Migita, K. (2020) · Medicine · doi:10.1097/md.0000000000022892 · Cited by 14
The Role of TIM-3 in Glioblastoma Progression
Ahmady, F., Sharma, A., Achuthan, A. A., Kannourakis, G., & Luwor, R. B. (2025) · Cells · doi:10.3390/cells14050346 · Cited by 14
Edmunds, G. L., Wong, C. C. W., Ambler, R., Milodowski, E., Alamir, H., Cross, S., Galea, G., Wülfing, C., & Morgan, D. J. (2022) · Communications Biology · doi:10.1038/s42003-021-02972-8 · Cited by 14
Dysfunction of circulating CD3+CD56+ NKT-like cells in type 2 diabetes mellitus
Tang, L., Wang, H., Cao, K., Xu, C., Ma, A., Zheng, M., Xu, Y., & Zhang, M. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.83317 · Cited by 13
Xiao, F., Hu, B., Si, Z., Yang, H., & Xie, J. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.04.011 · Cited by 15
LUI, S.-W., HSIEH, T.-Y., Lu, J., Chen, Y., Lin, T., Ho, Y., & Liu, F. (2023) · Apmis · doi:10.1111/apm.13341 · Cited by 13
Lim, J., Kurzrock, R., Nishizaki, D., Miyashita, H., Adashek, J. J., Lee, S., Pabla, S., Nesline, M., Conroy, J. M., DePietro, P., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6844 · Cited by 13
Update on current and new potential immunotherapies in breast cancer, from bench to bedside
Alaluf, E., Shalamov, M. M., & Sonnenblick, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1287824 · Cited by 12
Pernaa, N., Vakkuri, A., Arvonen, M., Kuismin, O., Santaniemi, W., Glumoff, V., Lappi‐Blanco, E., Lantto, U., Okkonen, M., Kaikkonen, K., et al. (2024) · Journal of Clinical Immunology · doi:10.1007/s10875-024-01685-x · Cited by 14
Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors
Guo, X., Yang, Y., Qian, Z., Chang, M., Zhao, Y., Ma, W., Wang, Y., & Xing, B. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216908 · Cited by 14
Werner, W., Kuzminskaya, M., Lurje, I., Tacke, F., & Hammerich, L. (2024) · Seminars in Liver Disease · doi:10.1055/a-2334-8311 · Cited by 14
Wu, X., Chen, P.-I., Whitener, R. L., MacDougall, M. S., Coykendall, V. M. N., Yan, H., Kim, Y. B., Harper, W., Pathak, S., Iliopoulou, B. P., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1415102 · Cited by 15
Beyond checkpoint inhibitors: the three generations of immunotherapy
John Schaub, & Tang, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01546-2 · Cited by 16
Sun, L., Zou, S., Ding, S., Du, X., Shen, Y., Liu, C., Shi, B., & Zhang, X. (2020) · Journal of Diabetes Research · doi:10.1155/2020/2583257 · Cited by 13
Emerging Therapies in the Treatment of Advanced Melanoma
Massand, S., & Neves, R. I. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.06.008 · Cited by 13
Capitani, N., Patrussi, L., & Baldari, C. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011221 · Cited by 15
Sharafi, F., Hasani, S. A., Alesaeidi, ., Kahrizi, M. S., Adili, A., Ghoreishizadeh, S., Shomali, N., Tamjidifar, R., Aslaminabad, R., & Akbari, M. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02682-z · Cited by 13
Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD)
Matsumoto, H., Fujita, Y., Matsuoka, N., Temmoku, J., Yashiro‐Furuya, M., Asano, T., Sato, S., Watanabe, H., Suzuki, E., Tsuji, S., et al. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02527-6 · Cited by 11
Timofeeva, A. M., Aulova, K. S., Mustaev, E. A., & Nevinsky, G. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188793 · Cited by 15
Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
Chu, P., & Chan, S. (2021) · Cancers · doi:10.3390/cancers13215295 · Cited by 11
Hong, J., Xia, L., Huang, Z., Yuan, X., Liang, X., Dai, J., Wu, Z., Li, L., Ruan, M., Long, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879471 · Cited by 12
Myeloid-derived suppressor cells in head and neck squamous cell carcinoma
He, J.-Y., Huo, F., Tang, H., Liu, B., & Bu, L. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.11.002 · Cited by 14
NK cells as powerful therapeutic tool in cancer immunotherapy
Huang, M., Liu, Y., Yan, Q., Miao, P., Ge, J., Mo, Y., Wang, Y., Wang, F., Zeng, Z., Li, Y., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-023-00909-3 · Cited by 12
TIM-3 inhibitors: a promising strategy for tumor immunotherapy
Lu, L., & Deng, L. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.01.004 · Cited by 12
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma
Haugh, A. M., & DAUD, A. I. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00841-0 · Cited by 12
Tiberio, L., Laffranchi, M., Zucchi, G., Salvi, V., Schioppa, T., Sozzani, S., Prete, A. D., & Bosisio, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360291 · Cited by 13
TIM-3 Expression on Dendritic Cells in Colorectal Cancer
Sakuma, M., Katagata, M., Okayama, H., Nakajima, S., Saito, K., Sato, T., Fukai, S., Tsumuraya, H., Onozawa, H., Sakamoto, W., et al. (2024) · Cancers · doi:10.3390/cancers16101888 · Cited by 12
Ledderose, S., Ledderose, C., & Ledderose, G. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155468 · Cited by 12
Zych, M., Kniotek, M., Roszczyk, A., Dabrowski, F. A., Jędra, R., & Zagożdżon, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179378 · Cited by 12
Bredholt, G., Sævik, M., Søyland, H., Ueland, T., Zhou, F., Pathirana, R. D., Madsen, A., Vahokoski, J., Lartey, S. L., Halvorsen, B. L., et al. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100564 · Cited by 13
Cai, Y., Han, Z., Shen, J., Zou, Z., Guo, J., Liang, Y., Li, S., Liao, H., Ren, Z., Peng, H., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01303-6 · Cited by 13
Fadriquela, A., Kim, C.-S., Lee, K., Kang, S. H., & Lee, J. (2021) · Alcohol · doi:10.1016/j.alcohol.2021.10.002 · Cited by 12
Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
Cavalieri, S., Filippini, D. M., Ottini, A., Bergamini, C., Resteghini, C., Colombo, E. V., Lombardo, R., Nuzzolese, I., Alfieri, S., Licitra, L. F., et al. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00062 · Cited by 12
Kuzevanova, A. Y., Апанович, Н. В., Mansorunov, D., Коротаева, А. А., & Karpukhin, A. V. (2022) · Biomedicines · doi:10.3390/biomedicines10092081 · Cited by 12
Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients
Domínguez‐Mozo, M. I., García-Frontini, M. C., Gómez-Calcerrada, M. I., Pérez‐Pérez, S., García‐Martínez, M. Á., Villar, L. M., Villarrubia, N., Costa‐Frossard, L., Arroyo, R., & Álvarez‐Lafuente, R. (2022) · Biology · doi:10.3390/biology11111633 · Cited by 11
Palacios, L. M., Peyret, V., Viano, M. E., Geysels, R. C., Chocobar, Y. A., Volpini, X., Pellizas, C. G., Nicola, J. P., Motrán, C. C., Rodriguez‐Galán, M. C., et al. (2022) · Biology · doi:10.3390/biology11111609 · Cited by 12
Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus
Nakamura, H., Konnai, S., Okagawa, T., Maekawa, N., Sajiki, Y., Watari, K., KAMITANI, K., Saito, M., Kato, Y., Suzuki, Y., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01430-22 · Cited by 12
Witzleben, A. V., Fehn, A., Grages, A., Ezić, J., Jeske, S. S., Puntigam, L. K., Brunner, C., Kraus, J. M., Kestler, H. A., Doescher, J., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33446 · Cited by 14
Ajarrag, S., & St‐Pierre, Y. (2021) · Cancers · doi:10.3390/cancers13215533 · Cited by 13
The Effects of Tamoxifen on Tolerogenic Cells in Cancer
Idris, R. A. M., Mussa, A., Ahmad, S., Al-Hatamleh, M. A. I., Hassan, R., Din, T. A. D. A. T., Rahman, W. F. W. A., Lazim, N. M., Boer, J. C., Plebanski, M., et al. (2022) · Biology · doi:10.3390/biology11081225 · Cited by 12
Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity
Yang, L., Li, S., Chen, L., & Zhang, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0241 · Cited by 10
Galectin-9 is a target for the treatment of cancer: A patent review
Rodrigues, C. F., Santos, F. A., Amorim, L. A. A., da Silva, A. L. C., Marques, L. G. A., & Rocha, B. A. M. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127768 · Cited by 11
Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice
Sorkhabi, A. D., Komijani, E., Sarkesh, A., Shadbad, P. G., Aghebati‐Maleki, A., & Maleki, L. A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01289-9 · Cited by 11
Innovative drugs promote precision cancer therapy
Huang, X., Zhu, M., Chen, R., Ni, J., Zhao, W., Li, S., Lü, X., Jiao, H., & Cao, X. (2023) · Clinical Cancer Bulletin · doi:10.1007/s44272-023-00002-8 · Cited by 12
Tao, J., Zeng, Z., He, C., Lin, M., Zhou, W., Ren, Y., Ma, X., Wang, Z., Liu, J., Li, D., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01046 · Cited by 11
Wang, C., Wu, Y. J., Zheng, J.-W., Huang, L. Y., Tan, K.-P., & Chen, J.-Y. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01024-7 · Cited by 11
Yado, S., Dassa, B., Zoabi, R., Reich-Zeliger, S., Friedman, N., & Geiger, B. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009011 · Cited by 12
Contemporary Approaches to Immunotherapy of Solid Tumors
Kuznetsova, A. V., Glukhova, K. А., Попова, О. П., Beletsky, I. P., & Aa, I. (2024) · Cancers · doi:10.3390/cancers16122270 · Cited by 14
Hu, W., Li, D., Yang, Y., Zheng, Y., Zeng, J., & Sai, K. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112665 · Cited by 11
Singh, A., Miranda Bedate, A., von Richthofen, H. J., Vijver, S. V., van der Vlist, M., Kuhn, R., Yermanos, A., Kuball, J. J., Kesmir, C., Pascoal Ramos, M. I., et al. (2024) · eLife · doi:10.7554/elife.92870.3 · Cited by 11
de Graav, G. N., Udomkarnjananun, S., Baan, C. C., Reinders, M. E. J., Roodnat, J. I., de Winter, B. C. M., & Hesselink, D. A. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001275 · Cited by 11
Moshkelgosha, S., Levy, L., Safavi, S., Karunagaran, S., Wilson, G. W., Renaud-Picard, B., Madu, G., Ramchandani, R., Oliver, J., Watanabe, T., et al. (2025) · Science Advances · doi:10.1126/sciadv.adp9052 · Cited by 11
Emerging Immunotherapy Targets in Early Drug Development
Araujo, D. M., Catani, G., Mirallas, O., Pretelli, G., Sánchez-Pérez, V., Vieito, M., Braña, I., Pujol‐Borrell, R., Garralda, E., & Hernando‐Calvo, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115394 · Cited by 12
Ocker, M., Mayr, C., Kiesslich, T., Stintzing, S., & Neureiter, D. (2021) · Cancers · doi:10.3390/cancers13071558 · Cited by 11
Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer
Lu, X. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210806120904 · Cited by 11
The study of immune checkpoint inhibitors in chronic hepatitis B virus infection
Li, S., Li, N., Yang, S., Deng, H., Li, Y., Wang, Y., Jiaqiang, Y., Lv, J., Dong, L., Yu, G., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108842 · Cited by 11
An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
Soleimanian, S., Alyasin, S. S., Sepahi, N., Ghahramani, Z., Kanannejad, Z., Yaghobi, R., & Karimi, M. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884879 · Cited by 11
Jiang, J., Cao, Z., Li, X., Li, B., Yu, S., Yang, B., Liu, Y., Zhai, F., Wang, R., & Cheng, X. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2022.105021 · Cited by 12
Current status and future perspectives of bispecific antibodies in the treatment of lung cancer
Wang, W., Qiu, T., Li, F., & Ren, S. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002460 · Cited by 11
Immune signatures in variant syndromes of primary biliary cholangitis and autoimmune hepatitis
Schultheiß, C., Steinmann, S., Willscher, E., Paschold, L., Lohse, A. W., & Binder, M. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000123 · Cited by 11
Insights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas
Jani, S., Church, C. D., & Nghiem, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172913 · Cited by 11
Koukourakis, I. M., Platoni, K., TINIAKOS, D. G., Kouloulias, V., & Zygogianni, A. G. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45050285 · Cited by 12
Chajuwan, T., Kansuwan, P., Kobbuaklee, S., & Chanswangphuwana, C. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1984454 · Cited by 11
Novel classes of immunotherapy for breast cancer
Hernando‐Calvo, A., Cescon, D. W., & Bedard, P. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06405-2 · Cited by 11
Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Kapoor, S., Champion, G., Basu, A., Mariampillai, A., & Olnes, M. J. (2021) · Cancers · doi:10.3390/cancers13195026 · Cited by 11
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer
Sanborn, R. E., Schneiders, F. L., Senan, S., & Gadgeel, S. M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350967 · Cited by 12
Jin, J., Tu, J., Ren, J., Cai, Y., Chen, W., Zhang, L., Zhang, Q., & Zhu, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.784925 · Cited by 10
TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma
Valente, S., Nascimento, C., Gameiro, A., Ferreira, J. A., Correia, J., & Ferreira, F. (2023) · Cancers · doi:10.3390/cancers15020384 · Cited by 10
GS-TCGA: Gene Set-Based Analysis of The Cancer Genome Atlas
Baird, T., & Roychoudhuri, R. (2024) · Journal of Computational Biology · doi:10.1089/cmb.2023.0278 · Cited by 10
Rethinking Immune Check Point Inhibitors Use in Liver Transplantation: Implications and Resistance
Ortiz, V., & Loeuillard, E. J. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101407 · Cited by 11
Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation
Ahmady, F., Curpen, P., Perriman, L., Teixeira, A. F., Wu, S., Zhu, H., Poddar, A., Jayachandran, A., Kannourakis, G., & Luwor, R. B. (2024) · Cells · doi:10.3390/cells13211777 · Cited by 10
Sun, H., Huang, D., Zhang, H., Dong, M., Wang, S., Sun, M., Liu, J., Wang, Y., Qu, X., Li, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70030 · Cited by 12
Synthesis and Biological Studies of O3‐Aryl Galactosides as Galectin Inhibitors
Kervefors, G., Pal, K. B., Tolnai, G. L., Mahanti, M., Leffler, H., Nilsson, U. J., & Olofsson, B. (2020) · Helvetica Chimica Acta · doi:10.1002/hlca.202000220 · Cited by 10
Giudice, V., Serio, B., Ferrara, I., Manzo, P., Gorrese, M., Pepe, R., Bertolini, A., D’Alto, F., Verdesca, F., Langella, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1052060 · Cited by 10
Biomarkers for early complications post hematopoietic cell transplantation: Insights and challenges
Balakrishnan, B., Kulkarni, U., Pai, A., Illangeswaran, R., Mohanan, E., Mathews, V., George, B., & Balasubramanian, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100306 · Cited by 7
Cong, Y., Liu, J., Chen, G., & Qiao, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.723238 · Cited by 10
Type 1 Cytotoxic T Cells Increase in Placenta after Intrauterine Inflammation
Liu, J., Liu, Y., Panda, S., Liu, A., Lei, J., & Burd, I. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718563 · Cited by 10
Wang, J., Yang, L., Dao, F., Wang, Y., Chang, Y. Z., Xu, N., Chen, W., Jiang, Q., Jiang, H., Liu, Y., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1966785 · Cited by 10
Zhang, S., Chen, S., Wang, Z., Li, J., Yuan, Y., Feng, W., Li, W., Chen, M., & Liu, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1061597 · Cited by 10
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Boldajipour, B., Lee, G., & Albertson, T. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2305296 · Cited by 10
Dietary protein modulates intestinal dendritic cells to establish mucosal homeostasis
Moreira, T. G., Cox, L. M., Silva, P. D., Mangani, D., Oliveira, M. G. D., Escobar, G., Lanser, T. B., Murphy, L., Lobo, E. L. C., Milstein, O., et al. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.06.006 · Cited by 9
Self-citationDeNiro, G., Que, K., Fujimoto, T., Koo, S. M., Schneider, B., Mukhopadhyay, A., Kim, J. G., Sawant, A., & Nguyen, T. A. (2024) · Cytometry Part A · doi:10.1002/cyto.a.24886 · Cited by 9
Parkin activates innate immunity and promotes antitumor immune responses
Perego, M., Yeon, M., Agarwal, E., Milcarek, A. T., Bertolini, I., Camisaschi, C., Ghosh, J. C., Tang, H., Grandvaux, N., Ruscetti, M. A., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180983 · Cited by 9
TIM-3 on myeloid cells promotes pulmonary inflammation through increased production of galectin-3
Kim, K. S., Lee, C., Kim, H.-S., Gu, S. J., Yoon, H. J., Won, S. B., Lee, H., Lee, Y. S., Kim, S. S., Kane, L., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06762-w · Cited by 10
Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells
Testa, U., Castelli, G., & Pelosi, E. (2024) · Cancers · doi:10.3390/cancers16213627 · Cited by 9
NFIL3/Tim3 axis regulates effector Th1 inflammation in COPD mice
Ke, J., Huang, S., He, Z., Lei, S., Lin, S., Li, Y., Li, Q., Huang, H., Huang, H., Qin, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1482213 · Cited by 9
Immune cell dysfunction: A critical player in development of diabetes complications
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Kyada, A., Malathi, H., Nathiya, D., Bhanot, D., Sameer, H. N., Hamad, A. K., Athab, Z. H., et al. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103510 · Cited by 11
Human γδ T Cell Function Is Impaired Upon Mevalonate Pathway Inhibition
Suen, T. K., Al, B., Ulas, T., Reusch, N., Bahrar, H., Bekkering, S., Bhat, J., Kabelitz, D., Schultze, J. L., van de Veerdonk, F. L., et al. (2025) · Immunology · doi:10.1111/imm.13931 · Cited by 9
Immune checkpoint inhibitors: From friend to foe
Rajak, P. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102033 · Cited by 9
Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma
Wang, Y., Rosell, R., Hirsch, F. R., Lu, S., Govindan, R., Park, K., Peters, S., & Zhang, J. J. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.11.008 · Cited by 11
Metadata
- Authors
- Wolf, Y., Anderson, A. C., & Kuchroo, V. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kuchroo, Vijay K.
- Venue
- Nature Reviews Immunology
- Published
- 2019-11-01
- Volume
- 20
- Issue
- 3
- Pages
- 173-185
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7327798
- OpenAlex
- W2985205513
- Cited by
- 959
- References
- 159
- Citations by year
- 2026: 98 · 2025: 140 · 2024: 191 · 2023: 160 · 2022: 183 · 2021: 142 · 2020: 44
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA187975)
- National Institute of Allergy and Infectious Diseases (P01AI073748, P01AI056299, P01AI039671)
- National Institute of Neurological Disorders and Stroke (R01NS045937)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- TIM-3, inhibitory receptors, co-inhibitory receptors, immune checkpoint, T cell exhaustion, loss-of-function mutations, antitumor immunity, chronic viral infection, cancer immunotherapy
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Clinical Trials as Topic, Humans, Signal Transduction, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
